|1.||Aramaki, Toshiyuki: 1 article (01/2009)|
|2.||Fukushima, Naomi: 1 article (01/2009)|
|3.||Eguchi, Katsumi: 1 article (01/2009)|
|4.||Nakamura, Hideki: 1 article (01/2009)|
|5.||Nishiura, Yoshihiro: 1 article (01/2009)|
|6.||Nakamura, Tatsufumi: 1 article (01/2009)|
|7.||Ida, Hiroaki: 1 article (01/2009)|
|8.||Haupt, E: 1 article (02/2005)|
|9.||Ledermann, H: 1 article (02/2005)|
|10.||Köpcke, W: 1 article (02/2005)|
|1.||Diabetic Neuropathies (Diabetic Neuropathy)
02/01/2005 - "The aim of the study was to evaluate the efficacy of benfotiamine administered over three weeks (allithiamine; a lipid-soluble vitamin B1 prodrug with high bioavailability) to patients with diabetic polyneuropathy in a randomized, placebo-controlled, double-blind, two-center pilot study. "
01/01/1996 - "In a double-blind, randomized, controlled study, the effectiveness of treatment with a combination of Benfotiamine (an Allithiamine, a lipid-soluble derivative of vitamin B1 with high bioavailability) plus vitamin B6/B12 on objective parameters of neuropathy was studied over a period of 12 weeks on 24 diabetic patients with diabetic polyneuropathy. "
|2.||Tropical Spastic Paraparesis (Tropical Spastic Paraplegia)
01/01/2009 - "This study was conducted to construct a basis for a therapeutic strategy against human T-lymphotropic virus type-I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) using a compound that contained a disulfide moiety, prosultiamine, which is a homologue of allithiamine originally synthesized by allicin and thiamine-thiol, for the targeting of HTLV-I-infected cells. "
|4.||Vitamin B 6